Pharmaceutical company VIVUS (NASDAQ:VVUS) has been marketing its obesity drug, Qsymia, primarily to physicians -- but the drug's initial sales were far below what investors were expecting. Presumably under pressure to ramp up sales, VIVUS recently announced a consumer-targeted program that offers a two-week free trial to patients.

Is this the spark that VIVUS needs to get back on track, or will sales take another hit when Arena (NASDAQ:ARNA) and partner Eisai market their competing drug in early 2013?

In the following video, health care analysts Max Macaluso and Brenton Flynn discuss this new marketing approach and what VIVUS might need to do in order to increase revenue.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.